METEOR Trial: Age-Based Outcomes With Cabozantinib for Renal Cell Carcinoma
Posted: Monday, January 27, 2020
Cabozantinib improved progression-free survival, overall survival, and objective response rates compared with everolimus in patients with renal cell carcinoma in all age subgroups, according to the results of the phase III METEOR trial published in the European Journal of Cancer. Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, Boston, and colleagues suggest that additional studies are needed to better define outcomes with cabozantinib based on age.
Researchers focused on 658 patients; 394 patients (60%) were younger than age 65, 201 (30.5%) were between the ages of 65 and 74, and 63 (9.5%) were at least 75 years of age. The overall survival rate for patients remaining on treatment was 21% (42/196) for cabozantinib versus 7.6% (15/198) for everolimus in patients younger than age 65; 28% (30/107) versus 7.4% (7/94) for patients between the ages of 65 and 74; and 7.4% (2/27) versus 8.3% (3/36) for patients at least 75 years of age.
Progression-free survival was improved with cabozantinib compared with everolimus for all age subgroups: 7.4 versus 3.8 months for patients younger than age 65; 8.1 versus 3.9 months for patients between the ages of 65 and 74; and 9.4 versus 4.4 months for patients at least 75 years of age. A higher objective response rate was observed with cabozantinib than with everolimus for the same three age subgroups as well: 15% versus 5%; 21% versus 2%; and 19% versus 0%.
Although the results indicate improved outcomes with cabozantinib compared with everolimus in each age category, “Older patients more frequently discontinued or required dose reductions due to adverse events,” the authors noted. “Older patients may benefit from proactive dose modification and supportive care to mitigate adverse events while retaining efficacy.”
Disclosure: The authors’ disclosures can be found at ejcancer.com.